IO Biotech, Inc. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported net loss was USD 71.46 million compared to USD 67.88 million a year ago. Basic loss per share from continuing operations was USD 2.48 compared to USD 17.3 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.17 USD | -0.85% | -4.88% | -37.77% |
May. 15 | HC Wainwright Adjusts IO Biotech Price Target to $12 From $8, Maintains Buy Rating | MT |
May. 14 | IO Biotech, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-37.77% | 77.74M | |
+21.85% | 46.93B | |
+37.63% | 39.08B | |
-8.05% | 38.48B | |
+29.04% | 31.01B | |
-13.75% | 26.14B | |
+10.65% | 25.88B | |
+38.43% | 12.53B | |
-6.92% | 11.36B | |
-12.29% | 10.65B |
- Stock Market
- Equities
- IOBT Stock
- News IO Biotech, Inc.
- IO Biotech, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022